| Literature DB >> 19961955 |
Craig P Carden1, Debashis Sarker, Sophie Postel-Vinay, Timothy A Yap, Gerthardt Attard, Udai Banerji, Michelle D Garrett, George V Thomas, Paul Workman, Stan B Kaye, Johann S de Bono.
Abstract
Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents. Copyright (c) 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19961955 DOI： 10.1016/j.drudis.2009.11.006
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851